TP53 is involved in the regulation of the cell cycle, response to DNA damage and induction of apoptosis. Mutations in this gene are thought to contribute to the development, progression or both of a variety of tumors, including human malignant glioma. Molecular analyses of primary malignant gliomas have demonstrated cellular heterogeneity in gene loss, rearrangement, amplification, transcription and translation. Furthermore, the rapid recurrence of this tumor demonstrates the presence of cells that are intrinsically resistant to therapy. Whether mutations in TP53 contribute to therapy resistance and tumor recurrence in malignant gliomas is not known. To determine if TP53 mutations are indicative of cells with a selective advantage that contributes to the survival and/or recurrence of glial tumors, we undertook a study to compare matched cells from primary and recurrent tumors from the same patients. We will present results from our analysis of TP53 mutations present in cells derived from both primary and recurrent glial tumors using polymerase chain reaction and sequence analysis to screen for mutations in exons 5-8 of TP53.
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Using universal human reference RNA in microarray gene expression studies Neuroblastoma is a common pediatric solid tumor that is frequently incurable. Biological risk stratification implicates amplification of the MYCN oncogene as a robust marker for poor prognosis. We have undertaken an analysis of gene expression in MYCN-amplified and non-amplified neuroblastoma tumors based on complementary DNA microarrays to advance our knowledge of the pathogenesis of this aggressive disease. We isolated messenger RNA from tumor cell primary cultures of two INSS stage 4 neuroblastoma patients, one with MYCN amplification and the other with normal MYCN copy number. Relative gene expression was determined after hybridization of the fluorophore-labeled cDNAs to a human cDNA microarray representing over 6,800 unique expressed genes. Using a differential gene expression ratio of 3.5 as a screening criterion, we identified 370 unique genes for further analysis. Of these, 78 were upregulated in the MYCNamplified neuroblastoma and 292 had decreased expression. Amplification correlated with increased transcript levels of genes associated with cell proliferation, including cell cycle regulatory genes such as CDC2 and CDC28 protein kinase, and the Ki-67 antigen, as well as many other annotated molecules not previously linked to MYCN amplification and several uncharacterized expressed sequence tag sequences. A coherent group of genes was downregulated in the MYCN-amplified cells, including the genes for the class I and class II major histocompatibility complex antigens, the gene for peptide antigen transporter TAP1, and several interferon responsive transcripts. MYCN amplification correlates with a distinct gene expression pattern in neuroblastoma that is consistent with the clinical phenotype of these tumors. Further characterization of this motif should enable the development of new therapies for these difficult tumors.
